GSK Consumer Healthcare announced its Q3 CY12 results on 01 Nov 2012. The company's Net Sales increased by 15% YOY to 858 crore and EBITDA increased by 20% YOY to INR171 crore. EBITDA Margin of the company increased from 19.1% to 19.9% YOY. PAT of the company increased by 25% YOY to INR129 crore. We maintain Our Price Target of INR3642 for the Stock.